Presentations include results from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy to antidepressants ...

This 72-year-old male presented to the dermatology clinic complaining of a pruritic rash on the top of his left foot. The rash is very itchy and, while in bed, he scratches it with the toenails of ...

On day 18, he noticed an erythematous, pruritic rash on both arms. By day 19, the rash significantly worsened, spread to his torso, and included urticaria with welts. On day 20, the rash continued ...

Reactions have included pruritus, rash (e.g., allergic dermatitis, papular rash, and generalized rash), and urticaria. Drug Interactions: CAPLYTA should not be used with CYP3A4 inducers.

Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today announced the publication of ...

MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of ...

Reactions have included pruritus, rash (e.g., allergic dermatitis, papular rash, and generalized rash), and urticaria. Drug Interactions: CAPLYTA should not be used with CYP3A4 inducers.